My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
June 2009
Vol. 19 No. 6
Patient Care and Science
IDSA Lyme Disease Review Panel Hearing Scheduled for July 30

IDSA will hold an all-day hearing of its Lyme Disease Review Panel on July 30, from 8 a.m. to 5 p.m. Eastern Daylight Time, to hear testimony from patients, physicians, and scientists regarding IDSA’s current Lyme disease guidelines.

Although in-person attendance is by invitation only, the hearing will be broadcast live via webcast and will be archived on the IDSA website. Information on how to view the webcast will be posted on the IDSA website no later than one week before the hearing. For more information about the hearing, please visit this page. Also see this item for an update on legislation in Connecticut related to Lyme disease treatment.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Top Stories
IDSA Issues New Guideline for Intravascular Catheter-Related Infections
Pandemic Designation Doesn’t Alter H1N1 Response (Yet)
IDSA Journal Club
Patient Care and Science
IDSA Lyme Disease Review Panel Hearing Scheduled for July 30
SHEA Issues Statement on H1N1 Infection Control
Drug Approvals, Recalls, Adverse Events Update
Practice Management
New “Ask the Coder” Service Answers CPT Questions
Deadline for Identify Theft Policies Extended to Aug. 1
New PQRI Reporting Period Begins July 1
Global ID
Global Center Urges U.S. Response to HIV/AIDS and TB Co-Infection
Highlights from the HIV/AIDS Implementers’ Meeting in Namibia
Policy and Advocacy
HIVMA Supports Public Plan Option for Health Care Reform
Your Colleagues
Members on the Move
Welcome, New Members!

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.